Stromal marker predicting radiotherapy benefit in DCIS
Predictive biomarkers are urgently needed to support the individualisation of radiotherapy for DCIS. Most efforts have focused on tumor cell features rather than the associated stroma. Our recent study by Strell et al. published in Clinical Cancer Research1 suggests, that high expression of the stroma cell marker platelet-derived growth factor beta (PDGFRb) can identify DCIS patients’ refractory to adjuvant radiotherapy.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.